Signed in as:
filler@godaddy.com
About Cells Matter
CELLS MATTER!
Cells Matter is a Scientific Affairs consulting firm for the advanced therapies ecosystem.
We help advanced therapies companies, enabling technology providers, collection organizations, and venture capital firms translate complex science into strategic clarity, credible communication, stakeholder education, technology evaluation, and market-facing insight.
Our work sits at the intersection of science, strategy, communication, and market understanding. Whether a company is clarifying its scientific story, evaluating a new technology, preparing for market engagement, or building Scientific Affairs capacity before hiring internally, Cells Matter helps turn technical complexity into practical direction.
The goal is simple: help organizations communicate and act on science with greater clarity, credibility, and strategic purpose.
What We Do
Cells Matter provides Scientific Affairs consulting for organizations working across advanced therapies, cell therapy, cellular starting material, enabling technologies, collection infrastructure, quality systems, biomanufacturing, and related investment or market strategy.
Our work includes scientific positioning and messaging, technology and platform evaluation, scientific due diligence support, thought leadership and technical content, customer and stakeholder education, conference field intelligence, customer-informed market strategy, and fractional Scientific Affairs support.
Across these services, Cells Matter helps clients move from technical capability to practical strategy: what to say, who needs to hear it, what evidence supports it, and what next steps make sense.
Why Scientific Affairs?
Advanced therapies companies operate in an environment shaped by biology, manufacturing realities, quality expectations, regulatory-adjacent considerations, customer needs, market education gaps, and evolving scientific standards.
Scientific Affairs helps organizations connect those moving parts.
It connects scientific expertise to external understanding, internal alignment, customer education, market credibility, and strategic decision-making. For many growing companies, the need for Scientific Affairs emerges before they are ready to build a full in-house function.
Cells Matter provides that capability on a flexible consulting basis, helping clients define their scientific point of view, educate sophisticated audiences, prepare for strategic market engagement, and build trust around the science behind their platform, product, or service.
Why Cells Matter?
Cells Matter was built on a core belief: cell-based therapies depend on the quality, consistency, and context of the cells that support them.
That perspective began with cellular starting material, where donor biology, collection practices, product handling, processing, cryopreservation, shipping, quality systems, and manufacturing expectations all shape downstream success. The original CSM Consulting brand focused on helping collection centers and cell therapy companies improve starting material strategy and pre-manufacturing alignment.
Today, that same perspective has expanded into a broader Scientific Affairs practice.
Cells Matter still brings deep expertise in cellular starting material, donor strategy, blood center operations, and CGT manufacturing support. The broader practice builds from that foundation, applying the same scientific and operational lens to technology evaluation, customer insight, market strategy, technical communication, stakeholder education, and Scientific Affairs function support.
This rebrand reflects the work we are already doing: helping organizations connect cellular science and advanced therapies complexity to the decisions, messages, and market understanding that move programs forward.
About our Founder and CSO:
Jennifer Chain, PhD, CABP
Jennifer Chain, PhD, CABP, CAPM is the Founder and CSO of Cells Matter. She brings nearly three decades of experience across immunology, technology and product development, cellular therapy, blood center operations, cellular starting material strategy, quality systems, regulatory frameworks, scientific education, and advanced therapies consulting.
Dr. Chain began her scientific career in 1998 at the Oklahoma Medical Research Foundation and earned her PhD in Immunology from the University of Oklahoma Health Sciences Center in 2005. Her academic and postdoctoral research focused on T cell development, activation, memory, γδ T cells, autoimmunity, cellular and molecular biology, and new method development.
After academic research and biotech experience, Dr. Chain moved into blood center innovation and cell therapy support. At the Oklahoma Blood Institute and CytoGrowth Solutions, she led research and development efforts that included new laboratory processes, manufacturing procedures, ancillary materials development, donor recruitment strategies, and cellular product collection programs. Under her leadership and coordination, more than 1,000 cell therapy products, including mobilized and non-mobilized leukopaks and bone marrow were collected from healthy donors over a three-year period to support research and therapy development. This work represented a 3X expansion in the number of clients served and generation of over $3.5M in departmental revenue.
Through Cells Matter, Dr. Chain supports organizations across the advanced therapies ecosystem with Scientific Affairs strategy, thought leadership, value chain mapping, customer-informed market strategy, technology evaluation, and business development support. Jenny’s consulting work helps companies translate complex cell therapy, cellular starting material, quality, manufacturing, and operational concepts into credible messaging, technical content, stakeholder education, and practical strategic direction. She has supported biotech companies, technology providers, collection organizations, CDMOs, and industry partners in clarifying product-market fit, mapping customer needs, developing scientific narratives, evaluating market opportunities, and aligning scientific, commercial, and operational priorities.
Dr. Chain’s background gives her a rare perspective across the advanced therapies value chain: she understands the science, the cells, the collection environment, the quality and regulatory expectations, the operational realities, and how to explain complex technical issues clearly to customers, partners, investors, and internal teams.
SELECTED PUBLIC WORK
Dr. Chain’s public work reflects the same Scientific Affairs approach Cells Matter brings to client engagements: translating complex advanced therapies, cellular starting material, quality, and biomanufacturing topics into clear, credible content for scientific and industry audiences.
Articles & Thought Leadership
The Leukopak Lady Educational Video Series
Client & Partner Content
Selected public-facing content and collaborations include:
White Paper for BCA on LRS Chambers vs Buffy Coats
Supporting Blog Posts on LRS Chambers for BCA
Scientific and Technical Blogs for Lumacyte
AABB Affiliate Consultant Profile and Educational Contributions